Login to Your Account

Aptevo lands $74.5M sale, regains rights to prostate cancer candidate

By Michael Fitzhugh
Staff Writer

Friday, September 1, 2017

Shares of Seattle-based Aptevo Therapeutics Inc. rose 58.7 percent on Friday to $2.11 as the company unveiled the sale of three noncore hematology drugs for up to $74.5 million to Saol Therapeutics.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription